Diabetic Macular Oedema (DMO) is associated with diabetic retinopathy and may be appeared in any stage of the disease. This condition is one of the main macular diseases, among the age-related macular degeneration (AMD), central retinal vein occlusion (CRVO) and vitreomacular traction (VMT). According to the Greek vitreoretinal company, more than 50.000 people are affected by a macular disease. In particular, 30% of diabetic patients, who have diabetes over 20 years will be affected by DMO. Unless the oedema does not be treated with drugs, these patients will soon have a vision decrease.
What is the Diabetic Macular Oedema (DMO)?
In case of diabetes, high glucose levels may lead to destruction of some blood vessels in retina. These vessels become weaker and may leak liquid or even be occluded. The accumulation of liquid between the retinal layers is called DMO. DMO is the most important cause of vision decrease in diabetic patients.
The disruption of the blood-retinal barrier leads to leakage of plasma components in the surrounding retina, leading to retinal oedema.
The decrease of vision can be ≥ 2 lines on the visual acuity chart in case of non-treatment administration in 50% of the patients.
The prevalence of visual impairment due to DMO depends on the type of diabetes and its duration.
In diabetic patients, the prevalence of the clinically significant macular oedema (CSMO) is about 6-10%.
Several studies have shown that 0.6% of general population is affected by CSMO.